Most recent papers in the journal Leukemia & Lymphoma

#1

JOURNAL ARTICLE

RUNX1 together with DAT mutations predicted poor outcome in acute myeloid leukemia.

Jinyan Xiao, Jundan Xie, Biqi Zhou, Yujie Liu, Jing Lu, Airui Jiang, Hong Yao, Qiaocheng Qiu, Zixuan Ding, Shengli Xue, Xiaowen Tang, Huiying Qiu, Suning Chen, Hongjie Shen, Depei Wu, Yang Xu

We retrospectively explored the prognostic impact of DAT mutations at diagnosis in 122 RUNX1mut AML patients. RUNX1 missense mutation was dominant in the RUNT domain, and frameshift mutation was dominant in the TAD domain. DAT mutations occurred in 38.5% of RUNX1mut AML. After propensity score matching, DATpos patients had worse two-year relapse-free survival (RFS) than DATneg patients ( p = .041). Moreover, RUNX1high (VAF ≥ 37.6%) patients showed poorer two-year overall survival (OS) and RFS than RUNX1low (VAF < 37...

36964663

March 24, 2023: Leukemia & Lymphoma

#2

JOURNAL ARTICLE

Using next generation sequencing to guide treatment of co-existing T-cell lymphoma and chronic myelomonocytic leukemia.

Ross T Salvaris, Benjamin Allanson, Chan Y Cheah

No abstract text is available yet for this article.

36961966

March 24, 2023: Leukemia & Lymphoma

#3

JOURNAL ARTICLE

EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort.

Prashasti Agrawal, Kevin A David, Zhengming Chen, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin, Samuel Singer, Mary-Kate Malecek, Jordan Carter, Adam Zayac, Myung Sun Kim, Nishitha Reddy, Douglas Ney, Alma Habib, Christopher Strouse, Jerome Graber, Veronika Bachanova, Sidra Salman, Jean A Vendiola, Nasheed Hossain, Mazie Tsang, Ajay Major, Maher K Gandhi, Colm Keane, David A Bond, Matthew Folstad, Julie Chang, Angel Mier-Hicks, Pallawi Torka, Priya Rajakumar, Parameswaran Venugopal, Stephanie Berg, Michael Glantz, Samuel A Goldlust, Rahul Matnani, Pallavi Kumar, Thomas A Ollila, Johnny Cai, Stephen E Spurgeon, Alex G Sieg, Joseph Cleveland, Narendranath Epperla, Reem Karmali, Seema Naik, Sonali M Smith, James L Rubenstein, Brad S Kahl, Amy Chadburn, Andrew M Evens, Peter Martin

The objective of this multicenter retrospective study was to examine the incidence, patient characteristics, pathology, and outcomes associated with Epstein-Barr virus (EBV)-related CNS lymphoma (CNSL) in older patients. Among 309 CNSL patients aged ≥60, 11.7% had EBV + tumors of which 72.2% were solid organ transplant (SOT)-related post-transplant lymphoproliferative disorders (PTLD). Younger age, SOT or autoimmune disease, and immunosuppressive treatment correlated highly with EBV-positivity...

36960939

March 24, 2023: Leukemia & Lymphoma

#4

JOURNAL ARTICLE

Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group.

Maximiliano Ramia de Cap, Leo P Wu, Christian Hirt, German A Pihan, Sanjay S Patel, Wayne Tam, Carlos E Bueso-Ramos, Rashmi Kanagal-Shamanna, Philipp W Raess, Alexa Siddon, Damodaran Narayanan, Elizabeth A Morgan, Geraldine S Pinkus, Emily F Mason, Eric D Hsi, Heesun J Rogers, Laura Toth, Kathryn Foucar, Stephanie N Hurwitz, Adam Bagg, Anton Rets, Tracy I George, Attilio Orazi, Daniel A Arber, Robert P Hasserjian, Olga K Weinberg

Myeloid sarcoma (MS) is currently considered equivalent to de novo acute myeloid leukemia (AML); however, the relationship between these entities is poorly understood. This retrospective multi-institutional cohort study compared 43 MS with NPM1 mutation to 106 AML with NPM1 mutation. Compared to AML, MS had more frequent cytogenetic abnormalities including complex karyotype ( p = .009 and p = .007, respectively) and was enriched in mutations of genes involved in histone modification, including ASXL1 ( p = ...

36960680

March 24, 2023: Leukemia & Lymphoma

#5

JOURNAL ARTICLE

The impact of mild-to-moderate chronic kidney disease on hospitalization outcomes in patients with acute myeloid leukemia.

Mohammad Ammad Ud Din, Hassan Saeed, Moazzam Shahzad, Hania Liaqat, Kendra Sweet

No abstract text is available yet for this article.

36938919

March 20, 2023: Leukemia & Lymphoma

#6

JOURNAL ARTICLE

Exposure to phenoxyacetic acids and glyphosate as risk factors for non-Hodgkin lymphoma- pooled analysis of three Swedish case-control studies including the sub-type hairy cell leukemia.

Lennart Hardell, Michael Carlberg, Marie Nordström, Mikael Eriksson

The association between pesticide exposure and non-Hodgkin lymphoma (NHL) including hairy cell leukemia (HCL) was analyzed in a pooled study of three case-control studies. Results on exposure to pesticides were based on 1,425 cases and 2,157 controls participating in the studies. Exposures were assessed by self-administered questionnaires completed as needed by phone. In the pooled univariate analyses adjusted by age, gender and year of diagnosis, exposure to herbicides of the phenoxyacetic acid type yielded statistically significant increased risk with odds ratio (OR) = 1...

36938909

March 20, 2023: Leukemia & Lymphoma

#7

JOURNAL ARTICLE

Phase II study of dose-adjusted EPOCH as initial therapy for adults with high-risk acute lymphoblastic leukemia.

Ryan D Cassaday, Lucas C Zarling, Kelsey-Leigh A Garcia, Olga Sala-Torra, Philip A Stevenson, Christen H Martino, Yajuan J Liu, Min Fang, Mary-Elizabeth M Percival, Anna B Halpern, Pamela S Becker, Vivian G Oehler, Andrei R Shustov, Jason P Cooper, Johnnie J Orozco, Paul C Hendrie, Roland B Walter, Jerald P Radich, Lorinda A Soma, Elihu H Estey

Treatments for adults with newly-diagnosed acute lymphoblastic leukemia (ALL) may be prohibitively toxic and/or resource-intense. To address this, we performed a phase II study of dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-EPOCH). Imatinib or dasatinib was added for Ph + disease; rituximab was added when CD20+. Fifty-three patients were evaluable: 28 with Ph + disease, and 25 with Ph-. All patients had ≥1 high-risk clinical feature...

36938892

March 20, 2023: Leukemia & Lymphoma

#8

JOURNAL ARTICLE

Virtual care for multiple myeloma in the COVID-19 era: interrupted time series analysis of veterans health administration data.

Christopher T Su, Jason C Chen, Jeremy B Sussman

No abstract text is available yet for this article.

36924453

March 16, 2023: Leukemia & Lymphoma

#9

JOURNAL ARTICLE

Rebound of COVID-19 infection in patients with chronic lymphocytic leukemia treated for SARS-CoV-2 with Nirmatrelvir/Ritonavir or Molnupiravir.

Tamar Tadmor, Guy Melamed, Tal Patalon, Hilel Alapi, Lior Rokach

No abstract text is available yet for this article.

36912366

March 13, 2023: Leukemia & Lymphoma

#10

JOURNAL ARTICLE

Functional humoral and cellular response of monovalent COVID-19-vaccines against Omicron BA.2 variant of SARS-CoV-2 in patients with chronic lymphocytic leukemia.

Matteo Passerini, Tamar Ratishvili, Jonathon M Monroe, Zelalem Temesgen, Thomas E Witzig, Neil E Kay, Richard B Kennedy, Sameer A Parikh

We designed a prospective study to evaluate the humoral (using a surrogate virus neutralization test) and cellular (using an IFN-γ ELISpot) immune response among patients with chronic lymphocytic leukemia (CLL) against Wuhan-Hu-1 and Omicron BA.2 strains of SARS-CoV-2, after mRNA-based vaccination. The proportion of patients with a functional humoral response was higher among untreated CLL patients compared to treated CLL patients against both Wuhan-Hu-1 and Omicron BA.2 after the second and the third dose of vaccination, and at 12 months after the first dose...

36908110

March 12, 2023: Leukemia & Lymphoma

#11

JOURNAL ARTICLE

Wilms' tumor 1 expression combined with genetic mutations for prognostic assessment in MDS.

Danqi Pan, Wenshu Zhao, Qianli Jiang, Changxin Yin, Han He, Libin Liao, Jieyu Ye, Min Dai

Overexpression of Wilms' tumor ( WT1 ) is frequently observed in myelodysplastic syndrome (MDS), which has been proposed as a prognostic marker. However, the prognostic role of WT1 expression in different contexts remains to be fully elucidated. We retrospectively assessed the relationships between WT1 levels and preexisting prognostic factors to further investigate its prognostic role under different contexts. In our study, WT1 expression was positively correlated with WHO 2016 classification and IPSS-R stratification...

36905177

March 11, 2023: Leukemia & Lymphoma

#12

JOURNAL ARTICLE

Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?

Tadeusz Robak

No abstract text is available yet for this article.

36896574

March 10, 2023: Leukemia & Lymphoma

#13

JOURNAL ARTICLE

Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.

Noam E Kopmar, Ted Gooley, Niall Curley, Kathryn Russell, Carole Shaw, Kelda Schonhoff, John Lim, Anna B Halpern, Roland B Walter, Bart L Scott, Jacob Appelbaum, Paul C Hendrie, Elihu H Estey, Mary-Elizabeth M Percival

No abstract text is available yet for this article.

36896478

March 9, 2023: Leukemia & Lymphoma

#14

JOURNAL ARTICLE

Poor post-induction outcomes in patients with acute myeloid leukemia previously treated with hypomethylating agents.

Michelle Y Zhang, Megan Othus, Carole Shaw, Kelda G Schonhoff, Anna B Halpern, Jacob Appelbaum, Paul C Hendrie, Roland B Walter, Elihu H Estey, Mary-Elizabeth M Percival

Patients with acute myeloid leukemia (AML) who have failed hypomethylating agents (HMA) have a poor prognosis. We examined whether high intensity induction chemotherapy could abrogate negative outcomes in 270 patients with AML or other high-grade myeloid neoplasms. Prior HMA therapy was significantly associated with a lower overall survival (OS) as compared to a reference group of patients with secondary disease without prior HMA therapy (median 7.2 vs 13.1 months). In patients with prior HMA therapy, high intensity induction was associated with a non-significant trend toward longer OS (median 8...

36891630

March 8, 2023: Leukemia & Lymphoma

#15

JOURNAL ARTICLE

Should WE use flow cytometry to assess bone marrow involvement by lymphoma?

Rebeca Jurado, Mercè Aren, Marc Sorigue

No abstract text is available yet for this article.

36891627

March 8, 2023: Leukemia & Lymphoma

#16

JOURNAL ARTICLE

CAR T-cells and macrophages in large B-cell lymphoma: impact on toxicity and efficacy.

Ajlan Al Zaki, Dustin McCurry, Paolo Strati

Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 is the current standard of care for the treatment of relapsed refractory large B cell lymphoma, demonstrating impressive response rates in the second- and third-line setting. Despite these advances, this treatment strategy can result in significant toxicities, such as cytokine release syndrome or immune effector cell associated neurotoxicity syndrome. While the exact mechanisms of these immune-mediated toxicities are not clearly understood, emerging pre-clinical and clinical studies have revealed the pivotal role of myeloid cells, particularly macrophages, as key contributors to the efficacy of treatments and as crucial mediators of toxicity...

36891619

March 8, 2023: Leukemia & Lymphoma

#17

JOURNAL ARTICLE

Tolerability of acalabrutinib in patients with CLL: experience of a tertiary cancer care center.

Alicia McGhie, Jenessa Lee, Alessandra Ferrajoli, Adam J DiPippo

No abstract text is available yet for this article.

36891585

March 8, 2023: Leukemia & Lymphoma

#18

JOURNAL ARTICLE

A phase II study to evaluate the efficacy of low-dose rasburicase (1.5mg) in adolescent and adult acute leukemia and high-grade lymphomas with tumor lysis syndrome.

Swaratika Majumdar, Neha Sharma, Manju Sengar, Jayashree Thorat, Lingaraj Nayak, Avinash Bonda, Bhausaheb Bagal, Akhil Rajendra, Amit Sethi, Hasmukh Jain

The FDA recommended dose of rasburicase 0.2 mg/kg/day till the resolution of TLS or up to 5 days, might be in excess and is prohibitively expensive. The quality of evidence supporting low dose rasburicase is limited. The objective is to study the plasma uric acid response rate. This is a single center, non-randomised phase II study. Duration is 10 June 2017 till 30 July 2019. Study setting is at Adult Hematolymphoid Unit, Tata Memorial Center. Participants are patients with acute leukemia and high-grade lymphomas aged >/=18 years, with ECOG PS of 0-3, with either laboratory or clinical TLS...

36891578

March 8, 2023: Leukemia & Lymphoma

#19

JOURNAL ARTICLE

Effect of anti-CD38 monoclonal antibodies on hepatitis C virus replication in chronically infected patients with multiple myeloma: a prospective series.

Chia-Yu Chiu, Khalis Mustafayev, Hans C Lee, Elisabet E Manasanch, Eduardo Yepez Guevara, Harrys A Torres

No abstract text is available yet for this article.

36883878

March 8, 2023: Leukemia & Lymphoma

#20

JOURNAL ARTICLE

Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.